No abstract

BackgroundRecent studies have shown significant decline in the final cure rate after miltefosine treatment in visceral leishmaniasis. This study evaluates the efficacy of miltefosine in the treatment of post kala-azar dermal leishmaniasis (PKDL) patients recruited over a period of 5 years with 18 months of follow-up.MethodologyIn this study 86 confirmed cases of PKDL were treated with two different dosage regimens of miltefosine (Regimen I- 50mg twice daily for 90 days and Regimen II- 50 mg thrice for 60 days) and the clinical outcome assessed monthly. Cure/relapse was ascertained by clinical and histopathological examination, and measuring parasite burden by quantitative real-time PCR. In vitro susceptibility of parasites towards miltefosine was estimated at both promastigote and amastigote stages.ResultsSeventy three of eighty six patients completed the treatment and achieved clinical cure. Approximately 4% (3/73) patients relapsed by the end of 12 months follow-up, while a total of 15% (11/73) relapsed by the end of 18 months. Relapse rate was significantly higher in regimen II (31%) compared to regimen I (10.5%)(P<0.005). Parasite load at the pre-treatment stage was significantly higher (P<0.005) in cases that relapsed compared to the cases that remained cured. In vitro susceptibility towards miltefosine of parasites isolated after relapse was significantly lower (>2 fold) in comparison with the pre-treatment isolates (P<0.005).ConclusionRelapse rate in PKDL following miltefosine treatment has increased substantially, indicating the need of introducing alternate drugs/ combination therapy with miltefosine.

Abstractobjective Confirmatory diagnosis of post-kala-azar dermal leishmaniasis (PKDL) is primarily based on invasive skin biopsy procedure. We evaluated the utility of minimally invasive slit aspirate specimen for serological and molecular diagnosis of PKDL. We compared the PKDL diagnosis using slit aspirate and skin biopsy specimens from the same patients.methods Serological diagnosis using rK39 strip test was performed with serum and slit aspirate sample; molecular diagnosis for parasite detection and quantification was carried out by quantitative real-time PCR (Q-PCR) with skin biopsy and slit aspirate sample.results The rK39 serological strip test was positive in all PKDL cases with both slit aspirate and serum samples (n = 50) and negative in all control cases (n = 24), giving a sensitivity of 100% (95% CI: 92.9-100%) and a specificity of 100% (95% CI: 86.2-100%). Quantitative-PCR detected parasite in all PKDL slit aspirates (n = 50, sensitivity = 100%, 95% CI: 92.9-100%) and tissue biopsies (n = 46, sensitivity = 100%, 95% CI: 92.3-100; it was negative in all controls including dermal tissues (n = 24) and slit aspirates (n = 24), giving specificity of 100% (95% CI: 86.2-100%). The parasite load in tissue and slit aspirate samples was significantly (P < 0.0001) correlated (r = 0.82).conclusions Slit aspirates are a simpler and minimally invasive sampling technique for initial screening by serology followed by confirmatory diagnosis of PKDL with microscopy and/or Q-PCR. The simplified procedure has the potential for epidemiological studies and assessment of cure in PKDL.